Premier Alternatives

Bluejay Therapeutics

Drug Discovery · Redwood City, CA · Founded 2019 · In IPO Registration

Developer of therapeutic medicines designed to provide curative treatments for serious viral and liver diseases. Bluejay Therapeutics is based in Redwood City, CA and was founded in 2019. Its last known valuation is $820 million. It has raised $243 million across 3 recorded rounds; the latest was an $182 million Series C in May 2024.

Last price · $/share
—
Implied valuation
$820.0M
Total raised
$243.0M
Last round
Later Stage VC (Series C)
May 2024

Bluejay Therapeutics key facts

  • Developer of therapeutic medicines designed to provide curative treatments for serious viral and liver diseases.
  • Bluejay Therapeutics’s last known valuation is $820.0M.
  • It has raised $243.0M across 3 recorded rounds; the latest was Later Stage VC (Series C) ($182.0M) in May 2024.
  • Notable investors include RA Capital Management, Novo Holdings, Wellington Management, T. Rowe Price Group, Frazier Healthcare Partners — 13 tracked in total.
  • Bluejay Therapeutics has filed 3 Form Ds with the SEC since 2021, most recently May 2024 ($182.0M sold to 19 investors).
  • Status: In IPO Registration.
Free account
More of Bluejay Therapeutics with a free account
  • ·The complete investor list: 13 names
  • ·Watch Bluejay Therapeutics: the Monday email on marks, rounds and moves
Create free account
No card required

Membership and data by Private Market View

Bluejay Therapeutics funding rounds

3 rounds
May 2024Later Stage VC (Series C)$182.0M▮
Aug 2022Early Stage VC$20.5MSEC filing▮
Jun 2021Early Stage VC$19.2MSEC filing▮
Full funding history →

Bluejay Therapeutics valuation

Bluejay Therapeutics's last known valuation is $820 million. The figure stands until a priced round, a secondary trade or an institutional fund mark prices the stock again.

How much has Bluejay Therapeutics raised?

Bluejay Therapeutics has raised $243 million across 3 recorded rounds since 2021. The largest was a $20.5 million early-stage round in Aug 2022; the most recent was an $182 million Series C in May 2024.

Bluejay Therapeutics has filed 3 Form Ds with the SEC since 2021, most recently in May 2024 ($182 million sold to 19 investors).

Bluejay Therapeutics investors

13 investors are on record for Bluejay Therapeutics, including RA Capital Management, Novo Holdings, Wellington Management and T. Rowe Price Group. The Series C in May 2024 drew 8 investors.

Comparable companies

Comparable drug discovery names by valuation on PrivateMarketView: Parabilis Medicines ($920 million), Abcuro ($700 million) and Candid Therapeutics ($657 million).

About Bluejay Therapeutics

Developer of therapeutic medicines designed to provide curative treatments for serious viral and liver diseases. The company's treatment focuses on reducing viral surface antigen monoclonal antibodies for the restoration of adaptive immunity starting with chronic hepatitis B (CHB) and chronic hepatitis D (CHD), enabling patients to improve their immunity and recover from infection.

Industry
Drug Discovery
Sector
Healthcare
HQ
Redwood City, CA, United States
Founded
2019
Employees
38
Ownership
In IPO Registration

Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.

Valuation on record
$820.0M

Bluejay Therapeutics’s last known valuation. A PrivateMarketView mark is published once fund marks, secondary prints or a priced round let us confirm it.